Theriva Biologics
TOVX
19 hedge funds and large institutions have $707K invested in Theriva Biologics in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.
60% more capital invested
Capital invested by funds: $442K → $707K (+$265K)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
6% more funds holding
Funds holding: 18 → 19 (+1)
0% less ownership
Funds ownership: 0.03% → 0.03% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$76.5K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$41.6K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$23.3K |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$23K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$7.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$79K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$31.3K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$25K |
| 4 |
SCA
Snowden Capital Advisors
New York
|
-$14.9K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$1K |
TOVX Hedge Fund Activity: Q2 2020 in Review
19 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2020, worth a combined $707K — up 60% from $442K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TOVX positions and 6 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $76.5K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $79K sold.
- 19 institutional investors held Theriva Biologics (TOVX) as of Q2 2020, up from 18 in Q1 2020.
- Funds reported $707K of Theriva Biologics stock for Q2 2020, up 60% quarter-over-quarter.
- 7 funds opened new Theriva Biologics positions in Q2 2020 and 6 closed out, a net change of +1 holder.
- The largest Theriva Biologics buyer in Q2 2020 was Renaissance Technologies, an estimated $76.5K added.
- The largest Theriva Biologics seller in Q2 2020 was Susquehanna International Group, an estimated $79K sold.
Based on aggregated 13F filings for Q2 2020.